• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Reduced-Dose Apixaban was Noninferior to Full-Dose for Cancer-Associated Venous Thromboembolism

byJinny TsangandAlisha Yi
April 22, 2025
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click here to read this study in NEJM.

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Ivonescimab improves survival in advanced non-small cell lung cancer

#VisualAbstract: Dapagliflozin Reduced Death and Worsening Heart Failure in Transcatheter Aor-tic-Valve Implantation

Sotorasib plus panitumumab may be a promising treatment option for colorectal cancer

Tags: apixabancancerefficacypulmonary embolismrctsafetyvenous thromboembolism (VTE)
Previous Post

#VisualAbstract: Tolebrutinib is Not Superior to Teriflunomide in the Treatment of Relapsing Multiple Sclerosis

Next Post

Ultrasound-guided radiofrequency ablation may be effective for treatment of aldosterone-producing adenomas

RelatedReports

Lessons from real-world implementation of lung cancer screening
Chronic Disease

Ivonescimab improves survival in advanced non-small cell lung cancer

April 30, 2025
#VisualAbstract: Dapagliflozin Reduced Death and Worsening Heart Failure in Transcatheter Aor-tic-Valve Implantation
StudyGraphics

#VisualAbstract: Dapagliflozin Reduced Death and Worsening Heart Failure in Transcatheter Aor-tic-Valve Implantation

April 18, 2025
Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs
Gastroenterology

Sotorasib plus panitumumab may be a promising treatment option for colorectal cancer

April 16, 2025
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Chronic Disease

Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism

April 14, 2025
Next Post

Ultrasound-guided radiofrequency ablation may be effective for treatment of aldosterone-producing adenomas

#VisualAbstract: Inebilizumab Improves Outcomes in Generalized Myasthenia Gravis

#VisualAbstract: Inebilizumab Improves Outcomes in Generalized Myasthenia Gravis

Levodopa for Parkinson’s disease more effective than newer generation therapies

Exenatide does not slow Parkinson’s disease progression compared to placebo

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
  • 2 Minute Medicine Rewind May 12, 2025
  • Self-perceived stress associated with increased risk of cryptogenic ischemic stroke
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.